Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study by Martínez Linares, José Manuel et al.
Research Article
Association of cardiovascular emerging risk factors with acute
coronary syndrome and stroke: A case-control study
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Abstract In this study, we estimated the risk of acute coronary syndrome and stroke associated with several emerging
cardiovascular risk factors. This was a case-control study, where an age- and sex-matched acute coronary
syndrome group and stroke group were compared with controls.Q4 Demographic and clinical data were collected
through patient interviews, and blood samples were taken for analysis. In the bivariate analysis, all cardiovascular
risk factors analyzed showed as predictors of acute coronary syndrome and stroke, except total cholesterol and
smoking. In the multivariate logistic regression model for acute coronary syndrome, hypertension and body mass
index, N-terminal section brain natriuretic peptide and pregnancy-associated plasma protein-Awere independent
predictors. For stroke, the predictors were hypertension, diabetes mellitus, body mass index, and N-terminal
section brain natriuretic peptide. Controlling for age, sex, and classical cardiovascular risk factors, N-terminal
section brain natriuretic peptide and pregnancy-associated plasma protein-A were independent emerging
cardiovascular risk factors for acute coronary syndrome, but pregnancy-associated plasma protein-A was not
for stroke. High levels of cardiovascular risk factors in individuals with no episodes of cardiovascular disease
requires the implementation of prevention programs, given that at least half of them are modifiable.
Key words acute coronary syndrome, cardiovascular disease, case-control study, risk factor, stroke.
INTRODUCTION
Cardiovascular disease (CVD) means any condition whose
origin is a vascular affectation, including acute coronary
syndrome, stroke, peripheral vascular disease, aortic athero-
sclerosis, and aortic aneurysms. The process which causes the
vast majority of vascular damages is atherosclerosis.
In the USA, this was the leading cause of death in 2011,
being responsible for nearly 30% of all deaths that occurred
(Hoyert & Xu, 2012). In the European Union (EU), it also
represents the primary cause of death, accounting for 39% of
all deaths in 2010 (European Commission, 2012Q5 ), which
resulted in a cost of €192 billionQ6 for the whole of the EU
(European Regional and Local Health Authorities, 2008).
In Spain, CVD is also the leading cause of death; in 2012, it
resulted in 30.3% of all deaths (Instituto Nacional de
Estadística, 2012).
According to the World Health Organization, in 2012 an
estimated 17.5 million people worldwide died from CVD,
representing 31% of all global deaths. Of these deaths, an esti-
mated 7.4millionwere due to acute coronary syndrome and 6.7
millionwere due to strokes (WorldHealthOrganization, 2015).
Therefore, both types of CVD are of paramount importance.
Cardiovascular risk (CVR) is defined as the probability of
suffering a cardiovascular event in a given period, which is
usually within 5–10 years, and cardiovascular risk factor
(CVRF), which is likewise defined as that measurable trait that
predicts an individual’s likelihood of developing CVD. The
most widely-accepted classification distinguishes between
adjustable CVRF and not by lifestyle, thus adding a third group
of emerging CVRF.
Literature review
A literature search was conducted in PubMed, Cochrane
Library, EMBASE, ERIC, IME, and the Scielo, database with
a maximum time limit of 5 years, except for those documents
deemed relevant to the study or those which referred to certain
related aspects that have not been published subsequently,
regarding significant developments in this field of research.
The descriptors used were cardiovascular diseases, risk factors,
acute coronary syndrome, and stroke. The selection of studies
was based on scientific quality items presented in its methodol-
ogy and available in any language, as long as at least the
summary of themost relevant data for evaluation was available
in English. Almost two-thirds of the used references were
journal articles or clinical practice guidelines published in the
past 5 years. The material utilized was selected because the
methodology used and the findings relating to emerging CVRF
were relevant to this study, emphasizing the relationship
between mentioned risk factors and both acute coronary
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syndrome and stroke, and the clinical implications of these
findings.
Pregnancy-associated plasma protein-A (PAPP-A) has been
suggested as a biomarker that produces instability and rupture
of atherosclerotic plaque (Bayes-Genis et al., 2001; Sangiorgi
et al., 2006Q7 ; You et al., 2010), and has also been observed in
animal models (Conover et al., 2010). Some studies have
demonstrated the association between PAPP-A and both
ischemic and hemorrhagic stroke (Fialová et al., 2006). In other
studies, PAPP-A is seen as a specific, sensitive, and early
biomarker for acute coronary syndrome (Li et al., 2013).
However, knowledge is lacking, both in relation to its method
of action in different situations and with regard to other impli-
cated co-substances, such as the insulin-like growth factor
(Conover, 2012; Lawrence et al., 1999).
Homocysteine has been identified as an independent risk
factor for acute coronary syndrome and stroke (Homocysteine
Studies Collaboration, 2002), and the association between
C-reactive protein (CRP) and homocysteine enables the
prediction of long-term mortality in young ischemic stroke
patients (Naess et al., 2013). Several randomized trials have
attempted to decrease blood homocysteine levels with vitamin
B dietary supplementation (Clarke et al., 2010; Martí-Carvajal
et al., 2015).
Different applications have been assigned to N-terminal
section brain natriuretic peptide (NT-proBNP) in several
studies, and an acceptable diagnostic value in distinguishing
ischemic stroke from other subtypes (Hajsadeghi et al., 2013)
also predicts presumable cardioembolic stroke independent
of coronary calcification (Kara et al., 2014; Yang et al., 2014).
Moreover, it is a significant predictor of major adverse cardio-
vascular events in stable coronary disease, as well as a strong
predictor of death and a wide range of cardiovascular events
(Linssen et al., 2010; Mishra et al., 2014) and some non-
cardiovascular causes (Oluleye et al., 2013).
The high-sensibility CRP (hsCRP) is presented in the scien-
tific literature as a good long-term predictor of mortality in
young ischemic stroke patients (Naess et al., 2013), and as a
strong, independent predictor of outcome in patients with acute
coronary syndrome (Fiechter et al., 2013). In addition, it is cited
as a predictor of death, not just from CVD, but also from some
non-cardiovascular causes (Oluleye et al., 2013), and as an
unfavorable long-term functional outcome in ischemic stroke
patients (Van Gilder et al., 2014).
Aim
The aim of this study was to estimate the risk of CVD, through
both acute coronary syndrome and stroke, associated with
various emerging CVRF (homocysteine, NT-proBNP, PAPP-
A, and hsCRP) in the town of Motril (Granada, Spain).
METHODS
Design
This case-control study was composed of 201 patients (67 acute
coronary syndrome, 67 stroke, and 67 controls), who were age
and sex matched. The patients were recruited from the
emergency unit of the Santa Ana Hospital (Granada, Spain),
and were diagnosed with acute coronary syndrome or stroke.
Q8Controls were also selected from those users who attended
the unit due to ophthalmic conditions or minor trauma.
Inclusion criteria for participants were acute coronary
syndrome admission diagnoses (acute myocardial infarction
or angina in whatever form) or stroke (hemorrhagic or ische-
mic), who remained as hospital inpatients and were not trans-
ferred to another referral hospital; people residing in the
vicinity of the hospital; and carers of people who had disabil-
ities. Likewise, the exclusion criteria were pregnant women;
and those suffering from acute or chronic inflammatory process
or cancer, acute or chronic kidney disease, acute or chronic
lung disease, and acute infectious processes.
Sample
The sample size was obtained using Epidat software (version
3.0; SERGAS,Galicia, Spain) based on the prevalence contrib-
uted by previous studies on emerging CVRF included in this
study. Homocysteine was the most representative variable in
presenting a greater uniformity in the values in different
studies. Thus, to achieve a power of 90% to detect differences
in the null hypothesis, H0: μ1=μ2, with a two-tailed t-test for
two independent samples, considering the significance level
was 5–15% over the number of patients for possible losses, it
was necessary to include 67 experimental units in the acute
coronary syndrome group, 67 in the stroke group, and 67 units
in the control group, which resulted in a total of 201 enrolled
participants.
The type of sample used for the selection of the acute
coronary syndrome group, the stroke group, and controls was
determined by systematic sampling, with a starting parameter
of 320 and an interval parameter of 756. Thus, acute coronary
syndrome and stroke were selected where the number of
admissions most closely approached the boot parameter range
and above, with a corresponding matched control starting from
the first day of data collection to complete the necessary
sample, which was from June 2011 to May 2013.
Ethical considerations
Approval was obtained from the Ethics Committee of the
Southern Health Agency of Granada. Furthermore, informed
consent from the patients before the collection of data from
each patient was provided. This included guaranteeing the
confidentiality of the obtained data. The study was conducted
in accordance with the provisions of the Declaration of
Helsinki.
Data collection
Data collection was conducted through interviews, during
which information about age, sex, admission, diagnosis, and
personal history of diagnosis of hypertension and diabetes
mellitus was obtained. Height and weight were measured with
a Seca 220 height–weight scale (Hamburg, Germany). Height
was measured without shoes, and weight was measured with
clothing on and empty pockets at hospital admission. The
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smoking habits of individuals were categorized into
“ex-smoker” if they had not utilized tobacco for at least 1 year,
“smoker” if they were currently utilizing tobacco and had been
doing so for at least 1 year, and “non-smoker” if they had never
smoked.
Blood determinations
Blood samples for the determination of total plasma
cholesterol and emerging CVRF under studywere drawn using
the peripheral venous puncture system Vacutainer (xxx, xxx,
xxx, xxxQ9 ) in the first 12 h after admission. They were then
analyzed in an EDTAQ10 tube that was kept cold until analysis
by in-vitro quantitative determination using an enzymatic
photometric test in a Roche Elecsys analyzer (Roche Diagnos-
tics, xxx,Q11 Spain). The measuring range was 3–750mg/dL
(0.08–19.4mmol/L), with ≤200mg/dL being desirable values
and >240mg/dL being high-risk values, and a stability of
20–25°C for 3 days, 7 days at 4–8°C, and 3months at 20°C.
The samples were centrifuged and analyzed within 2 h after
extraction.
For the determination of NT-proBNP and PAPP-A, tubes
with EDTA were utilized and immediately introduced into a
cooler with ice and transported to the laboratory where an
immunoassay for an in-vitro quantitative determination in
human plasma electroquimioluminiscenia immunoassay
(ECLIA) (Roche Elecsys automated analyzer; Roche
Diagnostics, Spain) was used.Q12 Elecsys proBNP contains two
polyclonal antibodies that recognize epitopes located in the
N-terminal proBNP, (stretch), for which a sandwich technique
is used with a total duration of 18min. The measuring range
of NT-proBNP was 5–35000pg/mL, which is considered
normal for values ≤100pg/mL for men and ≤150pg/mL for
women. The samples had a stability of 3 days at 20–25°C,
6 days at 2–8°C, and 12months at 20°C. Samples were
centrifuged prior to testing, and possible effects due to the
evaporation of samples, controls, and calibrators were deter-
mined within 2 h.
The same sandwich technique was used for the determina-
tion of PAPP-A, with a measuring range of 4–10,000 mIU/L.
Q13 The stability of the samples was 8 h at 15–25°C, 3 days at 2–8°
C, and 3months at 20°C.
In the case of hsCRP and homocysteine, an in-vitro quantita-
tive determination in human plasma by photometry using the
automatic analyzer Roche/Hitachi cobas c (Roche Diagnostics,
Spain), which was used in this study, was performed on a blood
sample collected in the tube with EDTA. The hsCRP test is
based on the principle of immune-enhanced agglutination test
particles. The measuring range in this case was 0.15–20mg/L
(1.43–190nmol/L), with a stability of 3 days at 15–25°C, 8 days
at 2–8°C, and 3 years at 15 to 25°C.Q14 The result considered
normal is<0.1mg/dL. Samples were kept cold and were centri-
fuged within 2 h. The samples were processed by homocysteine
photometry based on a novel principle that evaluates the
conversion product of the homocysteine cosubstrate. The
measurement range was 2.5–50mmol/L, with a stability of
4 days at 20–25°C, 4weeks at 0–8°C, and 4months at 20°C.
Q15 The normal range for adults is 5–100pg/mL.
Data analysis
A descriptive analysis of the variables was performed by calcu-
lating measures of central tendency and dispersion for numeric
variables, and absolute and relative frequencies for qualitative
variables. With the intention of utilizing the parametric and/or
non-parametric test, the normality of the variables prior to
the bivariate analysis Shapiro–Wilk test was confirmed. To test
whether there were differences between the three groups, for
numeric variables, analysis of variance (ANOVA) test or
Kruskal–Wallis test was used if the variables were not normal.
The χ2-test was used to measure the differences between
categorical variables, and a level of P< 0.05 was considered
significant. The relationship between the various traditional
and emerging biomarkers with the acute coronary syndrome
group and stroke group separately was analyzed using a multi-
variate logistic regression analysis. Furthermore, the variable
selection method was backward stepwise logistic regression,
where a level of P< 0.10 was considered significant. Analyses
were performed with free software R Project for Statistical
Computing version 3.0.3 (R Core Team, 2014).
RESULTS
The study population consisted of 102 men (50.75%) and 99
women (49.25%), divided into 67 acute coronary syndrome,
67 stroke, and 67 controls. No statistically-significant differ-
ences in the characteristics were found when considering the
matched characteristics between the three groups. The average
age of the acute coronary syndrome and stroke groups was
70.47 (standard deviation [SD]: 11.74) and 70.55 (SD: 11.73)
years, respectively. Both study groups had a body mass index
(BMI) classified as overweight or pre-obesity grade II
(BMI=27–29.9 kg/m2), which was the most predominant value
of BMI in acute coronary syndrome (25.37%), and the second
most prevalent in stroke (23.88%). In the case of controls, the
predominant group was the grade I overweight (BMI=25–
26.9 kg/m2) at 41.79%. Only 17.91% of the controls had a
BMI corresponding to normal weight (BMI=18.5-24.9kg/m2)
compared to 40.3% of the controls. The mean total cholesterol
values of the controls was greater than the mean of the two
study groups. In contrast, the levels of emerging CVRF in both
study groups were higher than those of the controls (Table T11).
After controlling for age and sex, most CVRF considered in
this studywere significantly different between each study group
and the control group. In the logistic regression analysis
performed for each study group, all CVRF behaved as signifi-
cant predictors of stroke or acute coronary syndrome, except
smoking and total cholesterol levels for the stroke group
(Table T22).
In the multivariate analysis, maintaining a significance level
of P< 0.05, for the acute coronary syndrome group, blood
pressure and BMI as adjustable CVRF, and NT-proBNP and
PAPP-A as emerging CVRF, continued to be significant, inde-
pendent predictors. For stroke, it was also the diabetes group,
but not PAPP-A (Table T33).
The area under the ROC Q16curve for the resulting model of
multivariate analysis for the SCA Q17group was 0.988, and 0.955
for the stroke group (Figs F11 and F22).
Cardiovascular emerging risk factors 3




































































































































Using amatched case-control design tominimize the confound-
ing effect, the hypertension, BMI, NT-proBNP, and PAPP-A
variables remained as predictors of acute coronary syndrome.
For stroke, it was also diabetes, but not PAPP-A (Table 3).
The high prevalence of hypertension in our elderly sample
was consistent with national estimates for this age group
(Mancia et al., 2013). In the control group, despite the lower
prevalence of hypertension, nearly one-quarter presented a
medium-high risk of CVD according to the SCORE Q20risk scale
adapted to the Spanish population (Sans et al., 2007), Q21which
Table 1. Comparison of clinical and demographic characteristics between acute coronary syndrome and stroke (n= 134) and controls (n= 67)†
Acute coronary syndrome group Stroke group Control group
Age (years) 70.4 ± 11.7 70.5 ± 11.7 70.1 ± 12.1
Sex (%) Male 34 (50.75%) 34 (50.75%) 34 (50.75%)
Female 33 (49.25%) 33 (49.25%) 33 (49.25%)
Diabetes mellitus (%) 23 (34.33%) 29 (43.28%) 3 (4.48%)
Hypertension (%) 47 (70.15%) 53 (79.1%) 10 (14.93)
Smoking (%) Yes (%) 15 (22.39%) 6 (8.96%) 10 (14.93%)
Exsmoker (%) 29 (43.28%) 23 (34.33%) 13 (19.40%)
No (%) 23 (34.33%) 38 (56.72%) 44 (65.75%)
Body mass index (kg/m2) 29.54 ± 4.98 28.11 ± 4.38 25.14 ± 3.04
Total colesterol (mg/dL) 175.02 ± 43.43 188± 35.90 192.02 ± 31.35
Homocystein (pg/mL) 14.34 ± 13.21 15.60 ± 10.09 9.74 ± 2.82
NT-proBNP (pg/mL) 2691.24 ± 705.60 2420.29 ± 448.34 46.23 ± 35.84
hsPCR (mg/dL) 2.09 ± 4.47 2.58 ± 5.39 0.31 ± 0.68
PAPP-A (mUI/L) 10.29 ± 7.64 7.38 ± 5.06 4.20 ± 1.21
†Means and standard deviations are shown for continuous variables; frequencies shown for categorical variables. hsPCR, high-sensibility C-reactive
protein; NT-proBNP, N-terminal brain natriuretic peptide; PAPP-A, pregnancy-associated plasma protein A.
Table 2. Bivariate conditional logistic regression model of emerging and classic cardiovascular risk factor for acute coronary syndrome and stroke in
Motril, Spain (n= 201)
Acute coronary syndrome OR (95% CI) P-value Stroke OR (95% CI) P-value
Hypertension 13.07 (5.33–34.82) <0.001 20.87 (8.17–58.70) <0.001
Diabetes mellitus 10.97 (3.04–60.53) <0.001 15.96 (4.49–87.27) <0.001
Smoking† Exsmoker 4.26 (1.90–10) <0.001 0.48 (0.21–1.08) 0.08
Smoker 2.86 (1.12–7.58) 0.02 1.43 (0.48–4.57) 0.51
Body mass index 1.34 (1.20–1.54) <0.001 1.26 (1.12–1.40) <0.001
Total cholesterol 0.98 (0.97–0.99) 0.010 0.99 (0.98–1.00) 0.582
NT-proBNP 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) <0.001
hsPCR 2.23 (1.22–4.07) 0.02 2.28 (1.24–4.16) 0.007
Homocystein 1.23 (1.11–1.35) <0.001 1.24 (1.13–1.36) <0.001
PAPP-A 2.08 (1.60–2.70) <0.001 1.91 (1.47–2.48) <0.001
Level of significance is P< 0.05. Reference group for both groups of cases is the control group. †Reference group is “non-smokers”. hsCRP, high-
sensibility C-reactive protein; NT-proBNP, N-terminal brain natriuretic peptide; OR, odds ratio; PAPP-A, pregnancy-associated plasma protein A;
95% CI, 95% confidence interval.
Table 3. Multivariate conditional logistic regressionmodel of emerging and classic cardiovascular risk factor for acute coronary syndrome and stroke
in Motril, Spain (n= 201)
Acute coronary syndrome OR (95% CI) P-value Stroke OR (95% CI) P-value
Diabetes mellitus –– NS 5.45 (1.82–36.32) 0.08
Hypertension 12.40 (6.97–21.45) 0.011 3.87 (1.00–14.96) 0.05
Body mass index 1.50 (1.05–2.57) 0.003 1.27 (1.08–1.56) 0.01
NT–proBNP 1.04 (1.02–1.08) <0.001 1.02 (1.01–1.03) <0.001
PAPP-A 2.91 (1.62–7.29) 0.002 –– NS
Level of significance is P< 0.10. NT-proBNP, N-terminal brain natriuretic peptide; NS, not significant; OR, odds ratio; PAPP-A, pregnancy-asso-
ciated plasma protein A; 95% CI, 95% confidence interval.
4 J. M. Martínez Linares et al.



































































































































enabled us to factor in the occurrence of future cardiovascular
events over the next 10years in the population, because
CVRF are modifiable through healthy lifestyles (Martínez
et al., 2014).Q22
Likewise, the high prevalence of diabetes in our population
is consistent with estimates by age and sex with the di@bet.es
Study on the prevalence of diabetes mellitus conducted in
Spain in 2012 (Soriguer et al., 2011), whereQ23 the prevalence in
the control group was much lower here than in the acute coro-
nary syndrome and stroke groups.
The means of the BMI show how the population of Motril
suffering CVD can be classified as overweight or pre-obesity
grade II, three-quarters of the aforementioned being above
the normal weight. These numbers are higher than the mean
of the Spanish population, among which nearly half present
with obesity or might be defined as being overweight
(Rodríguez et al., 2011). In addition, the average BMI of the
control group can be classified as overweight, which enables
us to anticipate future CVD events that could be avoided.
Currently, there is no evidence to justify the replacement of
BMI by any other form of measurement of overweight–obesity
( Q24European Society of Cardiology, 2012). One of the limitations
of the SCORE risk scale is that it does not include the BMI in
its algorithm, and given the independent association with
CVD, this is an important consideration thatmust be taken into
account when the CVR is evaluated.
In terms of total cholesterol, this does not appear as CVRF,
with statistical significance in both study groups, and the means
of the two study groups and the control group, being very sim-
ilar. Q25A similar occurrence takes place with smoking, which did
not appear to be statistically significant in the case of the stroke
group in the bivariate analysis, but was significant in the acute
coronary syndrome group. This significance disappears in the
multivariate analysis, because in the logistic regression analysis,
Figure 1. ROC curve model of Q18multivariate analysis of emerging and classic cardiovascular risk factors for acute coronary syndrome.
Figure 2. ROC curve Q19model of multivariate analysis of emerging and classic cardiovascular risk factors for stroke.
Cardiovascular emerging risk factors 5



































































































































the categories of “smoker” and “ex-smoker” did not show
statistical significance when compared with the “non-smoker”
group.
As an emerging CVRF in the acute coronary syndrome
group, NT-proBNP had a weak but statisti,cally-significant as-
sociation.Q26 Several studies have shown the relationship between
NT-proBNP and CVD as well as other causes of mortality in
the general population and in the population with coronary
heart disease, particularly among the elderly, including stroke
(Oluleye et al., 2013Q27 ; Linssen et al., 2010Q28 ; Mishra et al., 2014;
Odden et al., 2014). In Niu et al.’s study, the plasma concentra-
tion of NT-proBNP was closely related to the size of the
necrotic cardiac injury in patients with acute myocardial infarc-
tion and could be used to assess its size (Niu et al., 2014).
However, in our study, NT-proBNP showed a weak statistical
significance in the stroke group that disappeared on multivari-
ate analysis. This could be explained by the presence of cardio-
embolic stroke caused by atrial fibrillation, which produces
elevated NT-proBNP (Kara et al., 2014; Hajsadeghi et al.,
2013). In their meta-analysis, Yang et al. suggests that
NT-proBNP is a good useful diagnostic marker for
distinguishing cardioembolic stroke from other categories, with
the consequential benefit for these patients being the initiation
of preventive anticoagulant therapy (Yang et al., 2014).Moreover,
biochemical studies have indicated that cerebral ischemia gener-
ates NT-proBNP secretion by brain tissue (Nogami et al., 2001).
Our study demonstrates a relationship of PAPP-A to the
specific cardiovascular outcomes of acute coronary syndrome,
but not stroke, in the general population. PAPP-A has been
shown to be present in advanced stages of atherosclerosis,
and was significantly associated as CVRF with both study
groups in the bivariate analysis, but lost this significance to
stroke in the multivariate analysis (Li et al., 2013). Our results
support the findings of previous studies that showed PAPP-A
as a marker of unstable atherosclerotic plaques. PAPP-A is
produced by many cell types, both in reproductive (testicles
and endometrium) and non-reproductive tissues, including fi-
broblasts, vascular smooth muscle cells, and endothelial cells
(Conover, 2012) Moreover, macrophages can contribute to
PAPP-A overexpression due to the production of pro-
inflammatory cytokines interleukin-1β and tumor necrosis
factor-Q29 α. Degradation of some of these cytokines makes
PAPP-A help insulin-like growth factor-1 to carry out its action
(Lawrence et al., 1999) Therefore, PAPP-A has a very impor-
tant role in the development of atherosclerotic lesions in animal
models (Q30 Conover, 2010). In 2001, in one of the first studies con-
ducted by Bayes-Genis et al., patients with coronary disease
had levels of PAPP-A greater than those without this condition,
which was then proposed as a new, emerging CVRF in unstable
angina and acute myocardial infarction (Bayes-Genis et al.,
2001). A meta-analysis conducted by Li et al. of 14 studies
and 12,830 participants concluded that high levels of PAPP-A
are associated with adverse events in patients with coronary
heart diseaseQ31 (Li et al., 2013). PAPP-A has also been proposed
as an early marker of atherosclerotic plaque ruptureQ32 (Q33 You et al.,
2013; Sangiorgi et al., 2006). Moreover, in our study, no
statistically-significant association between levels of PAPP-A
and stroke was found; it was noted that there is minimal scien-
tific literature available regarding this. However, in studies,
such as those of Fialova et al., PAPP-A levels were elevated
in patients with intracranial hemorrhage or brain ischemia
(Fialová et al., 2006). Nevertheless, in most of these studies,
episodes of stroke occurred in patients with previous coronary
disease that could generate thrombus. More studies are there-
fore needed.
In our study, the other emerging CVRF analyzed demon-
strated no association with CVD.With regard to homocysteine,
a large number of epidemiological studies and meta-analyses
have shown that hyperhomocysteinemia is an independent risk
factor of atherosclerosis and thrombosis that is relevant in both
acute coronary syndrome and stroke (Homocysteine Studies
Collaboration, 2002; Zylberstein et al., 2004). In the same
way, treatment with folic acid to reduce levels of homocysteine,
and thus prevent cardiovascular events, has been unsuccessful
(Martí-Carvajal et al., 2015). However, other meta-analysis
have given less importance to this substance as a CVRF due
to the presence of confounding factors, such as metabolic nutri-
tional aspects and lifestyle (Clarke et al., 2010). Further to this,
hsCRP demonstrated a statistically-significant association with
both acute coronary syndrome and stroke in the univariate
analysis, an effect that disappeared in the multivariate analysis.
At present, the mechanism by which this substance would be
involved in CVD is not well clarified. However, its origin could
reside both in the presence of a complicated atherosclerotic
plaque and in a myocardial or cerebral necrosis. In this case,
several studies have linked hsPCR with CVD, both coronary
and cerebral, and as an independent predictor of CVRF in
the evolution and outcome after suffering a cardiovascular
event (Fiechter et al., 2013), (Naess et al., 2013). However,
a series of systematic reviews and meta-analyses published
in recent years have highlighted the need for more studies
(van Gilder et al., 2014).
The strength of this study is mainly the case-control design
used. This is the most appropriate for studying rare outcomes
of disease processes that develop during prolonged periods
(Argimón & Jiménez, 2013). It was the most suitable for study-
ing the association between a number of emerging CVRF and
CVD in its aspect of acute coronary syndrome and stroke, as
CVD is a pathophysiological process that develops over many
years, so transverse and longitudinal studies are inappropriate
for this population. In addition, a study of this kind has not
been conducted previously in the city of Granada (Spain).
Other strengths of this study include matching of the sample
by age and sex to minimize the important confounding effects
of them, and the consideration of classic CVRF that could also
have caused confounding effects.
Limitations
Despite careful design and analysis tailored to our working
conditions and economic possibilities for carrying it out, our
study has some limitations. First is its design as a case-control
study, which could limit the ability to generalize the findings.
However, our study could contribute to the design of studies
with different methodologies and conducted in a multicenter
way that serves to validate our results, generalize, and thus
improve future clinical practice.
6 J. M. Martínez Linares et al.



































































































































It is known thatmost CVDare caused by one ormore factors
known as CVRF, and in our study, we assumed that CVDwere
caused by these.Q34 However, we cannot absolutely conclude if
they were caused by some other CVRF that were not included
in this study. Besides this, we cannot ensure that the increase in
blood levels of emerging CVRF, less well known than the
classic CVRF, might have been high for unknown reasons,
and consequently, might have had confounding effects. Classic
CVRF were considered, and we corrected these, taking into
account any possible confounding effects they could have had.
Although the samples were manipulated using standard
procedures and following indications of the manufacturers of
reagents used for analysis, it is possible that pre-analytical
issues (i.e. storage) could have affected the stability of the
substances analyzed in the blood.
Conclusions
In summary, when taking into account the control of the
confounding effects of age, sex, hypertension, diabetesmellitus,
BMI, smoking, and total cholesterol, only NT-proBNP was
found to be an independent predictor for acute coronary
syndrome and stroke. However, PAPP-A was only found to
be a good independent predictor for acute coronary syndrome,
but not for stroke. The high levels of CVRF, both classical and
emerging, in individuals with no CVD episodes requires the
implementation of prevention programs, given that least half
of themaremodifiable, thereby further contributing to economic
savings for our public health system and society in general.
After controlling for age, sex, and classic CVRF, PAPP-A
was found to be a good predictor and biomarker of the specific
cardiovascular outcome acute coronary syndrome. Its etiology
and mechanism of action require further investigation. More-
over, the existence of studies andmeta-analyses with conflicting
results on the use of emerging cardiovascular risk factors that
were included in our study makes more research necessary. It
could therefore be concluded that based on sufficient evidence,
PAPP-A could be used for the determination of CVR, and
possibly be included in the prediction algorithms of CVR.Q35
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